InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Global X S&P Biotech ETF (CURE)
  6. Company Announcements

Global X S&P Biotech ETF (ASX: CURE) - Announcements

Current share price for CURE : $45.690 0.36 (0.79%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 CURE Annual Financial Report 4 Oct 2021 11:37AM $59.560 $45.690 fallen by 23.29%
$31 ETFS Units on Issue September 2021 1 Oct 2021 8:27AM $59.920 $45.690 fallen by 23.75%
$31 ETFS Units on Issue August 2021 1 Sep 2021 12:45PM $62.580 $45.690 fallen by 26.99%
$31 ETFS Units on Issue Jul 2021 2 Aug 2021 12:27PM $57.900 $45.690 fallen by 21.09%
$31 ETFS Units on Issue Jun 2021 2 Jul 2021 8:19AM $62.420 $45.690 fallen by 26.80%
$31 Update - Dividend/Distribution - CURE 1 Jul 2021 7:13PM $62.420 $45.690 fallen by 26.80%
$31 Update - Dividend/Distribution - CURE 30 Jun 2021 9:06AM $68.920 $45.690 fallen by 33.71%
$31 Update - Dividend/Distribution - CURE 30 Jun 2021 8:19AM $68.920 $45.690 fallen by 33.71%
$31 Dividend/Distribution - CURE 24 Jun 2021 6:14PM $67.340 $45.690 fallen by 32.15%
$31 ETFS Units on Issue May 29021 1 Jun 2021 4:06PM $62.670 $45.690 fallen by 27.09%
$31 ETFS Units on Issue April 2021 7 May 2021 12:10PM $61.430 $45.690 fallen by 25.62%
$31 ETFS Units on Issue March 2021 1 Apr 2021 10:01AM $67.540 $45.690 fallen by 32.35%
$31 ETFS Units on Issue January 2021 2 Feb 2021 9:25AM $76.060 $45.690 fallen by 39.93%
$31 ETFS Units on Issue December 2020 11 Jan 2021 8:40AM $72.650 $45.690 fallen by 37.11%
$31 ETFS Units on Issue November 2020 1 Dec 2020 9:45AM $67.540 $45.690 fallen by 32.35%
$31 ETFS Units on Issue October 2020 6 Nov 2020 5:35PM $63.520 $45.690 fallen by 28.07%
$31 ETFS Units on Issue September 2020 1 Oct 2020 6:44PM $59.300 $45.690 fallen by 22.95%
$31 CURE Annual Financial Report 24 Sep 2020 8:15AM $59.850 $45.690 fallen by 23.66%
$31 ETFS Units on Issue - August 2020 1 Sep 2020 8:50AM $56.640 $45.690 fallen by 19.33%
$31 ETFS Units on Issue - July 2020 3 Aug 2020 10:47AM $58.400 $45.690 fallen by 21.76%
$31 Update - Dividend/Distribution - CURE 1 Jul 2020 4:48PM $61.500 $45.690 fallen by 25.71%
$31 ETFS Units on Issue - June 2020 1 Jul 2020 8:18AM $61.200 $45.690 fallen by 25.34%
$31 Update - Dividend/Distribution - CURE 29 Jun 2020 12:06PM $68.240 $45.690 fallen by 33.05%
$31 Dividend/Distribution - CURE 24 Jun 2020 5:56PM $69.470 $45.690 fallen by 34.23%
$31 ETFS Units on Issue - May 2020 1 Jun 2020 9:46AM $65.200 $45.690 fallen by 29.92%

76 - 100 of 110 results

Page 4 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.